Corneal dendritic cells and the subbasal nerve plexus following neurotoxic treatment with oxaliplatin or paclitaxel

Autor:	Terry Trinh, Thomas Naduvilath, Craig R. Lewis, Kimberley Au, Jeremy Chung Bo Chiang, Jacob Klisser, Michael Friedlander, Maria Markoulli, Azadeh Tavakoli, Susanna B. Park, Arun V. Krishnan, David Goldstein
Jazyk:	angličtina
Rok vydání:	2021
Předmět:	Male Pathology medicine.medical_specialty Time Factors Paclitaxel Corneal diseases medicine.medical_treatment Science Antineoplastic Agents Article Cornea chemistry.chemical_compound Immune system Nerve Fibers medicine Humans Aged Chemotherapy Multidisciplinary Microscopy Confocal Cumulative dose business.industry Cancer Dendritic cell Dendritic Cells Middle Aged medicine.disease Oxaliplatin Cross-Sectional Studies Treatment Outcome chemistry Case-Control Studies Immunohistochemistry Medicine Female Neurotoxicity Syndromes Peripheral nervous system business medicine.drug
Zdroj:	Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021) Scientific Reports
ISSN:	2045-2322
Popis:	Immune cell infiltration has been implicated in neurotoxic chemotherapy for cancer treatment. However, our understanding of immune processes is still incomplete and current methods of observing immune cells are time consuming or invasive. Corneal dendritic cells are potent antigen-presenting cells and can be imaged with in-vivo corneal confocal microscopy. Corneal dendritic cell densities and nerve parameters in patients treated with neurotoxic chemotherapy were investigated. Patients treated for cancer with oxaliplatin (n = 39) or paclitaxel (n = 48), 3 to 24 months prior to assessment were recruited along with 40 healthy controls. Immature (ImDC), mature (MDC) and total dendritic cell densities (TotalDC), and corneal nerve parameters were analyzed from in-vivo corneal confocal microscopy images. ImDC was increased in the oxaliplatin group (Median, Md = 22.7 cells/mm2) compared to healthy controls (Md = 10.1 cells/mm2, p = 0.001), but not in the paclitaxel group (Md = 10.6 cells/mm2). ImDC was also associated with higher oxaliplatin cumulative dose (r = 0.33, p = 0.04) and treatment cycles (r = 0.40, p = 0.01). There was no significant difference in MDC between the three groups (p > 0.05). Corneal nerve parameters were reduced in both oxaliplatin and paclitaxel groups compared to healthy controls (p
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fccd0f8c290b7ff0c03557afe5d5ef1f https://doaj.org/article/00382dae9ddf41f08fab328294b408ea Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.